170 related articles for article (PubMed ID: 26930186)
1. Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide.
Schneider EL; Henise J; Reid R; Ashley GW; Santi DV
Bioconjug Chem; 2016 May; 27(5):1210-5. PubMed ID: 26930186
[TBL] [Abstract][Full Text] [Related]
2. Hydrogel drug delivery system with predictable and tunable drug release and degradation rates.
Ashley GW; Henise J; Reid R; Santi DV
Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2318-23. PubMed ID: 23345437
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneously Administered Self-Cleaving Hydrogel-Octreotide Conjugates Provide Very Long-Acting Octreotide.
Schneider EL; Henise J; Reid R; Ashley GW; Santi DV
Bioconjug Chem; 2016 Jul; 27(7):1638-44. PubMed ID: 27253622
[TBL] [Abstract][Full Text] [Related]
4. A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist.
Schneider EL; Hearn BR; Pfaff SJ; Reid R; Parkes DG; Vrang N; Ashley GW; Santi DV
ACS Chem Biol; 2017 Aug; 12(8):2107-2116. PubMed ID: 28605180
[TBL] [Abstract][Full Text] [Related]
5. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.
Santi DV; Schneider EL; Reid R; Robinson L; Ashley GW
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6211-6. PubMed ID: 22474378
[TBL] [Abstract][Full Text] [Related]
6. Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity.
Wang P; Zhuo X; Chu W; Tang X
Int J Pharm; 2017 Aug; 528(1-2):62-75. PubMed ID: 28579543
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
[TBL] [Abstract][Full Text] [Related]
8. Primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system.
Hearn BR; Fontaine SD; Pfaff SJ; Schneider EL; Henise J; Ashley GW; Santi DV
J Control Release; 2018 May; 278():74-79. PubMed ID: 29577950
[TBL] [Abstract][Full Text] [Related]
9. A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.
Schneider EL; Reid R; Parkes DG; Lutz TA; Ashley GW; Santi DV
Domest Anim Endocrinol; 2020 Jan; 70():106373. PubMed ID: 31479925
[TBL] [Abstract][Full Text] [Related]
10. An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.
Kim D; Jeon H; Ahn S; Choi WI; Kim S; Jon S
J Control Release; 2017 Jun; 256():114-120. PubMed ID: 28457895
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable tetra-PEG hydrogels as carriers for a releasable drug delivery system.
Henise J; Hearn BR; Ashley GW; Santi DV
Bioconjug Chem; 2015 Feb; 26(2):270-8. PubMed ID: 25584814
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.
Li X; Zhao Z; Li L; Zhou T; Lu W
Drug Deliv; 2015 Jan; 22(1):86-93. PubMed ID: 24467493
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.
Cirincione B; Edwards J; Mager DE
AAPS J; 2017 Mar; 19(2):487-496. PubMed ID: 27896683
[TBL] [Abstract][Full Text] [Related]
14. Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats.
Xuan J; Lin Y; Huang J; Yuan F; Li X; Lu Y; Zhang H; Liu J; Sun Z; Zou H; Chen Y; Gao J; Zhong Y
Peptides; 2013 Aug; 46():172-9. PubMed ID: 23770254
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies on the influences of primary emulsion preparation on properties of uniform-sized exenatide-loaded PLGA microspheres.
Qi F; Wu J; Hao D; Yang T; Ren Y; Ma G; Su Z
Pharm Res; 2014 Jun; 31(6):1566-74. PubMed ID: 24398695
[TBL] [Abstract][Full Text] [Related]
16. A long-acting C-natriuretic peptide for achondroplasia.
Schneider EL; Carreras CW; Reid R; Ashley GW; Santi DV
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2201067119. PubMed ID: 35858423
[TBL] [Abstract][Full Text] [Related]
17. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
18. Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy.
Tong F
Int J Nanomedicine; 2017; 12():4663-4678. PubMed ID: 28721043
[TBL] [Abstract][Full Text] [Related]
19. The use of low molecular weight protamine to enhance oral absorption of exenatide.
Zhang L; Shi Y; Song Y; Sun X; Zhang X; Sun K; Li Y
Int J Pharm; 2018 Aug; 547(1-2):265-273. PubMed ID: 29800739
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.
Zhang Y; Zhong Y; Hu M; Xiang N; Fu Y; Gong T; Zhang Z
Drug Dev Ind Pharm; 2016; 42(7):1042-9. PubMed ID: 26558908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
